
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
The PREDI-LYNCH project kicks off in Heidelberg.
Sep 22, 2025
Dave Tippett
The PREDI-LYNCH consortium officially launched its six-year Horizon Europe project with an in-person kick-off meeting in Heidelberg on September 18, 2025.
The event brought together over 50 researchers, clinicians, and partners from across Europe. Oslo Cancer cluster is one of the partners in the research and innovation project, wich consists of a consortium of 28 partners from 16 European countries.
Funded under the EU Mission on Cancer, PREDI-LYNCH unites leading institutions and experts to improve screening, diagnostics, and risk prediction for individuals with a hereditary predisposition to cancer. The project combines clinical research, data science, innovation, and stakeholder engagement to build scalable solutions that can be implemented in health systems across Europe.
Lynch syndrome is an inherited condition that increases a person’s risk of developing colorectal, endometrial, and several other cancers, often at a younger age than the general population. It’s one of the most common hereditary cancer syndromes, affecting about 1 in 300 people, yet many remain undiagnosed.
Early detection and tailored prevention can make a major difference for those living with the condition and their families.
Meeting face to face for the first time gave the international consortium an important opportunity to build connections, align on project goals, and set the foundation for close cooperation in the years ahead.
“This is a long and complex journey that requires trust, dialogue, and shared commitment. Being together in person is essential for building that common ground,” said project coordinator Mev Dominguez Valentin from Oslo University Hospital.
The program featured presentations from each work package, covering topics such as ethics and legal frameworks, liquid biopsies for Lynch syndrome cancers, validation of detection tests in multicenter trials, new early-detection modalities, and the integration of advanced AI-based risk prediction models.
Sessions also addressed health economics, data management, dissemination strategies, and sample logistics.
A post-event social activity organized by Oslo Cancer Cluster rounded off the day, underlining the value of community building in a project that spans countries, institutions, and disciplines.
With the Heidelberg meeting now concluded, the PREDI-LYNCH consortium is moving forward with a shared sense of purpose: to accelerate research and deliver practical tools that will help clinicians, patients, and families affected by Lynch syndrome.
More about PREDI-LYNCH on our project page.
14 October at 17.00-20.00 there will be a seminar about Lynch Syndrome and the Predi-Lynch project at the Norwegian Cancer Society in Oslo. Please follow this link from the Norwegian Cancer Society to sign up. To see the programme, please visit the Facebook event.
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.